RxDoctor Payments Data

Oluwafemi Showole, DO

Cardiovascular Disease · Midland, MINPI 1801150602

Payments from drug & device makers

$8,468in general payments, 2019–2025

Across 55 payments — averaging $153.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$5K
  • Amgen$2K
  • Boston Scientific$2K
  • Pfizer$237
  • Novartis$171
  • Genentech USA, Inc.$95
  • plus $191 from 4 others

What the payments were for

  • Travel & lodging$4,90071%
  • Food & beverage$2,01529%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,468 in reported general payments places this provider in the 65th percentile of 760 cardiovascular disease providers in Michigan.

See all cardiovascular disease providers in Michigan

Medicare billing

Part B allowed, 2024
$190,802
Medicare patients
3,316
Services billed
6,088

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban427$486,288
XareltoRivaroxaban86$111,678
JardianceEmpagliflozin33$45,570
Repatha SureclickEvolocumab45$39,520
EntrestoSacubitril/Valsartan34$29,917
FarxigaDapagliflozin Propanediol18$17,001
Bisoprolol Fumarate307$10,117
Metoprolol Succinate446$7,308
Rosuvastatin Calcium391$6,535
Atorvastatin Calcium369$5,953
ClopidogrelClopidogrel Bisulfate235$3,927
Isosorbide Mononitrate ErIsosorbide Mononitrate189$3,589
Carvedilol219$3,284
Ranolazine ErRanolazine37$3,164
Lisinopril261$2,070

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$237$486,288427 claims
NovartisEntresto$171$29,91734 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 760 cardiovascular disease providers in Michigan.

Other cardiovascular disease in Midland

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →